– Study findings confirm the importance of
improving education among clinicians and streamlining processes to
increase adoption of testing in routine cancer care –
SAN
FRANCISCO, May 26, 2023 /PRNewswire/
-- Invitae (NYSE: NVTA), a leading medical genetics
company, today announced nine studies to be presented at the 2023
American Society of Clinical Oncology (ASCO) Annual Meeting held in
Chicago from June 2-6, 2023. The new research insights
highlight innovations in genetic testing in a variety of clinical
settings, population groups and cancer types, and reinforce the
need to reduce barriers to genetic services to help patients
receive the most effective care and monitoring.
Presentation showcases learnings about the benefits of
germline genetic testing for lung cancer
patients (Saturday, June
3, 2023 at 12:30 p.m. CDT
and Monday, June 5, 2023
at 1 p.m. CDT)
Leading lung cancer expert and Invitae research partner,
Renato Martins, M.D., M.P.H.,
Virginia Commonwealth University (VCU)
Massey Cancer Center, will present findings from a retrospective
study of over 7,000 lung cancer patients who completed germline
genetic testing (GGT). Results of the study showed that 14.9% of
patients in this cohort had pathogenic germline variants (PGVs),
nearly all of which were clinically actionable. Dr. Martins will
share research highlights and key takeaways about how patients with
lung cancer can benefit from precision therapies based on PGVs in
addition to how this vital information informs future cancer
screening and family testing, which supports consideration for GGT
for patients with lung cancer.
Latest PROCLAIM trial findings illustrate how prostate cancer
patients experience the impact of genetic testing (Saturday, June 3, 2023 at 1:15 p.m. CDT)
Studies have shown that uptake for GGT in prostate patients
varies widely (10-60%) based on the stage of the disease, practice
setting and provider type. To better understand how patients
experience genetic testing, Invitae enrolled unselected prostate
cancer patients from 15 community urology practices to undergo
multigene panel testing and collected patient-reported outcomes via
surveys at least one month post GGT.
Most patients reported that their test results reduced their
concerns or did not impact their level of concern regarding their
cancer diagnosis, treatment or follow up. This study shows that
universal GGT was beneficial to prostate cancer patients and helped
to inform their treatment and follow-up decisions.
"Educational programs for germline genetic testing (GGT) for
community clinicians treating prostate cancer patients is essential
so they can successfully incorporate GGT into their practices,"
said Neal D. Shore, M.D., F.A.C.S.,
from the Carolina Urologic Research Center, and lead author of the
study. "When clinicians understand both the 'why' and the 'how' for
a successful testing program, then patients, their families and our
healthcare system will all benefit."
Population level data demonstrates support for universal
germline testing after a cancer diagnosis (Monday, June 5, 2023 at 3
p.m. CDT)
A study led by Allison Kurian,
M.D., M.Sc., at Stanford University, in
collaboration with Invitae and others, sought to better understand
the adoption of genetic testing and results across cancer types.
Using the statewide Surveillance Epidemiology and End Results
(SEER) registries in California
and Georgia, researchers were able
to link results from laboratories that provided nearly all GGT in
these regions to evaluate more than 1.3 million adult patients
diagnosed with all reported cancer types.
The study highlighted that GGT remains low across cancer types,
falling short of guidelines, and the gaps in rates of testing and
particularly the continued racial/ethnic disparities in testing are
critical areas for intervention that systematic implementation of
current universal testing guidelines may help to address. Genetic
testing use among patients for whom universal testing is currently
recommended were as follows: male breast cancer (50%), ovarian
cancer (38.6%), female breast cancer (26%), pancreatic cancer
(5.6%), colorectal cancer (5.6%) with testing use increasing over
time from 2013 to 2019. Additionally, results showed that compared
to non-Hispanic whites, patients from other racial/ethnic groups
received less testing without improvement over time, underscoring
the need to improve access to genetic testing for underserved
groups.
"Significant gaps persist in the uptake of germline genetic
testing across cancer types," stated W. Michael Korn, M.D., chief medical officer for
oncology at Invitae. "We continue to see evidence that the vast
majority of patients who qualify have not yet benefited from
testing. System-wide implementation of existing universal testing
guidelines is the most effective way to identify actionable results
that are currently missed, and essential to provide patients access
to germline-indicated precision therapies and clinical trials,
especially for underserved populations."
"The power of linking genetic testing results to SEER registry
data allows us to understand what is happening at the population
level – and to pinpoint where the gaps in testing lie," said
Kurian. "This is a crucial step towards closing those
gaps."
Study results show that novel approaches that aim to
streamline germline genetic testing can help eliminate barriers in
clinical practice
The research team at University of
Vermont Medical Center partnered with Invitae to explore a
novel and streamlined approach to genetic testing where patients
with advanced cancer were first tested and then offered genetic
counseling if a PGV was identified.
Patients who had been diagnosed recently (<1 year) with
metastatic cancer underwent germline testing accompanied by written
educational materials. Patients received outreach from a genetic
counselor only if their results showed a variant of uncertain
significance (phone call) or were positive for a PGV (phone call
plus invitation for clinic follow-up), while those with negative
results received a summary letter.
Patients and healthcare providers were given a survey to gauge
their satisfaction with the streamlined testing process. More than
94% of patients appreciated having undergone testing during an
existing appointment and 82% of participants felt confident that
they understood the results of their test. Every healthcare
provider who completed the survey was satisfied with the testing
process and 94% were interested in continuing with the new
approach. The study results show that there is interest from both
healthcare providers and patients to incorporate new processes that
remove barriers to genetic testing and facilitate seamless
integration into cancer care.
Improving access to genetic testing
Invitae is presenting additional research with its partners at
ASCO that supports the company's mission to bring comprehensive
genetic information into mainstream medicine to improve healthcare
for all. These findings underscore the importance of incorporating
genetic testing into the standard of care and improving access to
testing for underrepresented groups to aid in earlier diagnoses and
connect patients to clinical trials as well as precision
medicines.
2023 ASCO presentations:
- Education Session Arie Crown Theater, ASCO Plenary Series:
Rapid Abstract Updates: Titled: Landscape of Pathogenic
Germline Variants in Patients with Lung Cancer. Presenter:
Renato Martins, M.D., M.P.H. –
Saturday, June 3, 2023 at
12:30 p.m. CDT
- Education Session E451, Family Matters: Germline Testing in
Thoracic Cancers: Titled: Pathogenic Germline Alterations in
Lung Cancer. Presenter: Renato
Martins, M.D., M.P.H. – Monday, June
5, 2023 at 1 p.m. CDT.
- Oral Abstract Session S100a, Abstract 10500: Titled:
Germline genetic testing use and results after a cancer
diagnosis. Presenter: Allison W.
Kurian, M.D., M.Sc. – Monday, June 5,
2023 at 3 p.m. CDT.
2023 ASCO posters:
- Poster 240/Abstract 10607: Titled: Using
patient-reported outcomes to assess the impact of germline genetic
testing on prostate cancer patients. Presenter: Sarah M.
Nielsen Young, M.S. – Saturday, June 3, 2023 at 1:15 p.m. CDT.
- Poster 223/Abstract 10590: Titled: Rates of potentially
actionable germline variants in homologous recombination repair
genes in a large international cohort outside of the United States. Presenter: Sarah M. Nielsen Young, M.S. – Saturday, June 3, 2023 at 1:15 p.m. CDT.
- Poster 183/Abstract 10550: Titled: Disparities in
Germline Genetic Testing Results from a Cohort of ~493,515 Black
and White Patients. Presenter: Sarah M.
Nielsen Young, M.S. – Saturday, June
3, 2023 1:15 p.m. CDT.
- Poster 250/Abstract 10617: Titled: Eliminating barriers
to uptake of germline genetic testing for patients with advanced
cancer: the GTAC study. Presenter: Kara K.
Landry, M.D. – Saturday, June 3,
2023 at 1:15 p.m. CDT.
- Poster 224/Abstract 10591: Titled: Implementation of
universal pan-cancer germline genetic testing in an Arab
population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG)
study. Presenter: Hikmat Abdel-Razeq, M.D. – Saturday, June 3, 2023 at 1:15 p.m. CDT.
- Poster 448b/Abstract
TPS622: Titled: MRD assay evaluates recurrence and
response via a tumor informed assessment: MARIA-Breast
Observational Trial. Presenter: Ed
Esplin, M.D., Ph.D., FACP, CGAF, FACMG – Sunday, June 4, 2023 at 8
a.m. CDT.
- Poster 405/Abstract 4084: Titled: A novel
patient-centric longitudinal data registry platform to generate
insights into real-world cholangiocarcinoma (CCA) clinical
practice. Presenter: Amanda Nottke,
Ph.D. – Monday, June 5, 2023 at
8 a.m. CDT.
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram, Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the company's beliefs regarding the implications of its
new research; that the research reinforces the critical role of
germline genetic testing in oncology; and that the study findings
confirm the importance of improving education among clinicians and
streamlining processes to increase adoption of testing in routine
cancer care. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: the company's ability to grow its business in
a cost-efficient manner; the company's history of losses; the
company's ability to maintain important customer relationships; the
company's ability to compete; the company's need to scale its
infrastructure in advance of demand for its tests and to increase
demand for its tests; the risk that the company may not obtain or
maintain sufficient levels of reimbursement for its tests; the
applicability of clinical results to actual outcomes; risks
associated with litigation; the company's ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Invitae PR contact:
Renee
Kelley
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-research-insights-to-be-presented-by-invitae-at-the-2023-asco-annual-meeting-reinforce-the-critical-role-of-germline-genetic-testing-in-oncology-301835287.html
SOURCE Invitae Corporation